The improvement in net loss per share indicates a positive trend in Autolus Therapeutics' financial performance, which could be viewed favorably by investors. The substantial cash and equivalents position suggests financial stability and potential for future investments or operations without immediate need for additional financing. These factors combined are likely to have a positive short-term impact on AUTL's stock price.